PLG · healthcare · LATAMJul 202610 min read356 words

Product-led growth for Series B companies: scaling without breaking for healthcare and life sciences in Latin America

How Series B companies scale product-led growth across regions and teams without losing the discipline that made it work at Series A. Written for commercial leaders at healthtech, medtech, and life-sciences companies in Latin America.

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in Latin America. In this market, LATAM buyers reward hands-on partnership, local presence, and clear commercial terms, so the way you install product-led growth has to be shaped to that reality from day one.

Series B is the stress test for product-led growth. What worked at fifteen people fails at fifty unless the operating rhythm is deliberate.

The Series B move is to separate the model owner from the operators. One senior human owns strategy, self-serve activation to paid conversion, and the weekly review; a small team runs the machine.

Add a second geography or segment only when the first one is producing a defensible number for two full quarters. Not before.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in Latin America it is compounded by the fact that local partnership depth, not marketing spend is what actually gates growth. Product-led growth is only useful here when it is pointed at both constraints at once.

Governance appears at Series B — that is fine, provided it accelerates rather than slows. The test is whether reviews still make decisions or just distribute updates.

The Series B failure mode of product-led growth is bolting PLG onto a product that requires a demo to understand, amplified by headcount. Fix the root cause; do not paper over it with more people.

Compensation begins to matter now. Pay operators on self-serve activation to paid conversion outcomes, not on effort. Effort-based comp at Series B produces theatre.

A well-run product-led growth function at Series B is the moat that survives to Series C. Companies that skip this discipline burn through raises trying to buy it back.

Concretely for healthcare and life sciences in Latin America: the healthcare teams that install this get past procurement instead of dying in it, and one properly-installed LATAM account becomes a reference across the region. That is the reason it is worth installing product-led growth deliberately for this market rather than importing a playbook designed for somewhere else.

PLGproduct led growthself-servePLG for series Bscaling GTMPLG for healthcare and life sciencesPLG in Latin Americahealthcare and life sciences growth in Latin America

Frequently asked questions

PLG · healthcare · LATAM — answered

Does product-led growth work for healthcare and life sciences in Latin America?
Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in Latin America, LATAM buyers reward hands-on partnership, local presence, and clear commercial terms. The healthcare teams that install this get past procurement instead of dying in it.
How does product-led growth change at Series B?
Ownership separates from execution; operating rhythm gets more deliberate; governance appears.
When should we expand to a second region?
After the first region delivers two straight quarters of defensible self-serve activation to paid conversion.
What compensation model works for product-led growth operators at Series B?
Outcome-linked on self-serve activation to paid conversion, not activity-based.
What is the Series B stress point?
Bolting PLG onto a product that requires a demo to understand, amplified by headcount. Fix the root, not the symptom.
What is the LATAM-specific pitfall when running product-led growth for healthcare?
Importing a playbook that was built for another market. In Latin America, LATAM buyers reward hands-on partnership, local presence, and clear commercial terms — the install has to reflect that.

Growth Broker editorial

Filed under plg · healthcare · latam

Up next

AI for Growth: the complete 2026 guide for B2B companies

Read piece

Ready to broker your growth?

Book a Growth Call